Showing 712 results
-
Press release /Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile…
-
Ad hoc release /Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and…
-
Press release /Solides Wachstum (kWk[1]) im dritten Quartal beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie der fortzuführenden Geschäftsbereiche[2]: Der Nettoumsatz beläuft sich auf USD 12,3…
-
Press release /Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
-
Ad hoc release /Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by…
-
Press release /Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1] Detailed findings presented at World Ophthalmology Congress 2018…
-
Press release /Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera®, a first-in-class RadioLigand Therapy (…
-
Press release /Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was…
-
Press release /Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights…
-
Press release /Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc…